- Home
- PLX vs JRS Comparison
PLX vs JRS Comparison
Compare PLX & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- JRS
- Stock Information
- Founded
- PLX 1993
- JRS 2001
- Country
- PLX United States
- JRS United States
- Employees
- PLX N/A
- JRS N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- JRS Finance/Investors Services
- Sector
- PLX Health Care
- JRS Finance
- Exchange
- PLX Nasdaq
- JRS Nasdaq
- Market Cap
- PLX 204.9M
- JRS 231.7M
- IPO Year
- PLX 1998
- JRS N/A
- Fundamental
- Price
- PLX $2.19
- JRS $7.91
- Analyst Decision
- PLX Strong Buy
- JRS
- Analyst Count
- PLX 1
- JRS 0
- Target Price
- PLX $15.00
- JRS N/A
- AVG Volume (30 Days)
- PLX 934.1K
- JRS 86.6K
- Earning Date
- PLX 11-13-2025
- JRS 01-01-0001
- Dividend Yield
- PLX N/A
- JRS 8.87%
- EPS Growth
- PLX N/A
- JRS N/A
- EPS
- PLX 0.08
- JRS N/A
- Revenue
- PLX $61,948,000.00
- JRS N/A
- Revenue This Year
- PLX $14.53
- JRS N/A
- Revenue Next Year
- PLX $75.77
- JRS N/A
- P/E Ratio
- PLX $28.28
- JRS N/A
- Revenue Growth
- PLX 62.79
- JRS N/A
- 52 Week Low
- PLX $1.16
- JRS $5.95
- 52 Week High
- PLX $3.10
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- PLX 46.99
- JRS 38.44
- Support Level
- PLX $2.25
- JRS $7.88
- Resistance Level
- PLX $2.40
- JRS $8.02
- Average True Range (ATR)
- PLX 0.14
- JRS 0.08
- MACD
- PLX -0.02
- JRS -0.02
- Stochastic Oscillator
- PLX 40.70
- JRS 13.89
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.